explore -WSS

explore

author：focus 2025-10-01 00:47:53 - browse：746

A person wears five fitness tracking watches on their wrist — first opinion coverage from STAT — Bebeto Matthews/AP

Turn on your TV or open a web browser this January, and you’ll be bombarded with ads for fitness trackers, smart scales, health apps, and other digital innovations promising to streamline your journey to a happier and healthier you. It’s the time of year when we’re most susceptible to such messaging: Surveys show that at least one-third of our New Year’s resolutions focus on exercising, losing weight, or eating better.

That’s great news for the $45 billion fitness tracking industry, which spends vast sums on advertising designed to convince us that data is the key to better living. The marketing campaigns work: Each January, fitness app downloads spike 36% higher than usual. We’ve also seen the rise of over 400 personalized nutrition companies, while over 12 million people have sequenced their DNA through 23andMe.

Only one problem: The data isn’t working. At least 1.4 million Americans are diagnosed with diabetes each year. Obesity rates soared from 31% to 42% over the past decade. Life expectancy is declining. We were told data would put us in control, but we’re actually less healthy than ever.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： The creative science of coining drug names

WSS

As health system earnings go up, health insurance stocks go down

Maker of FluMist seeks to allow at

Novel spinal cord stimulator treats paralysis without surgery

Telehealth options flood the market as retailers push virtual care

As billionaires fund anti

The FDA weighs the risks of candy

Wikipedia

explore

leisure time

Psychedelics group wrestles with new pharma identity

Novel spinal cord stimulator treats paralysis without surgery

Medicare details structure of new drug price negotiation program

AI for drug discovery: Experts on separating hype from reality

Medicare details structure of new drug price negotiation program

Paying for Covid pills will soon shift to insurers

Trump demands the U.S. pay no more for drugs than other countries … again

As health system earnings go up, health insurance stocks go down

DIEP, the 'gold standard' of breast reconstruction, is under threat

The FDA weighs the risks of candy

knowledge

How a small hospital in rural Puerto Rico survived Hurricane Maria

Has Bernie Sanders reached the limit of his pharma bullying effort?

GSK’s asthma push continues as drug succeeds in Phase 3 trials

Crowdfunding for medical bills sidesteps core problem, author says

AI for drug discovery: Experts on separating hype from reality

Empower primary care with adequate payments and technology

explore

focus

hotspot

hotspot